ClinicalTrials.gg
Not yet recruitingNCT07915141Updated Nov 4, 2026

Effects of Upper Extremity Physiotherapy and Home Exercises on Functional Outcomes in Individuals With Stroke

An interventional study of Supervised Upper Extremity Physiotherapy Program and Home Exercise Program in Stroke, sponsored by Istanbul Gelisim University. Not yet recruiting at 2 sites in Turkey (Türkiye). Open to participants aged 30 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Istanbul Gelisim University · Not applicable, Interventional, and Treatment

Updated Nov 4, 2026Newly registeredGo to Updates ↓
Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Non-randomized
Ages
30 Years to 65 Years
Sex
All
01

Study summary

This study aims to investigate the effects of an upper extremity physiotherapy program combined with home exercises on activities of daily living, quality of life, joint range of motion, and pain in individuals with hemiplegia following stroke.

The study compares two groups: participants receiving supervised physiotherapy in addition to a home exercise program and participants performing a home exercise program only. The intervention includes stretching, range-of-motion exercises, arm ergometer training, progressive strengthening, coordination exercises, and fine motor activities.

The intervention period lasts 10 weeks. Outcomes are assessed using the Barthel Index, Short Form-36 (SF-36), Visual Analog Scale (VAS), goniometric measurements, and sensory assessments.

The study aims to evaluate whether adding supervised physiotherapy to home exercises provides additional benefits for upper extremity rehabilitation following stroke.

02

Conditions studied

  • Stroke

Keywords

  • Hemiplegia, Upper Extremity Rehabilitation, Physiotherapy, Home Exercise Program, Activities of Daily Living, Quality of Life
03

In context

Stroke

8,255 studies on the registry are indexed under Stroke; 2,056 are open to participants now.

This study's planned enrollment of 42 is below the median of 49 across 6,024 interventional studies indexed under Stroke.

Browse Stroke studies →

Lead sponsor

Istanbul Gelisim University is the lead sponsor of 64 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of stroke.
  • Age greater than 30 and less than 65 years.
  • Time since stroke between 1 and 5 years.
  • Voluntary participation in the study and treatment.
  • Upper extremity Brunnstrom recovery stage 2 or 3.
  • Ability to understand and perform the prescribed exercise program.

Exclusion criteria

Exclusion Criteria:

  • Unwillingness to continue participation in the study or treatment.
  • Irregular attendance at scheduled treatment sessions.
  • Upper extremity contracture severe enough to prevent exercise performance or range of motion assessment.
  • Spasticity severe enough to prevent safe and effective upper extremity exercise performance.
  • Failure to perform the prescribed home exercises regularly.
  • Development of an additional disease or medical condition affecting upper extremity function during the study.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
42 participants (estimated)

Study arms

  • Experimental
    Physiotherapy and Home Exercise Group

    Participants in this group receive supervised upper extremity physiotherapy twice a week for 45 minutes over 10 weeks, in addition to a home exercise program. The physiotherapy program includes stretching, passive and active-assisted range-of-motion exercises, arm ergometer training, progressive resistance exercises using Theraband and dumbbells, coordination exercises, and fine motor activities. The home exercise program is performed five days per week, twice daily for 30 minutes per session.

    Behavioral: Supervised Upper Extremity Physiotherapy Program · Behavioral: Home Exercise Program

  • Active comparator
    Home Exercise Group

    physiotherapy sessions. The program includes upper extremity range-of-motion exercises, stretching, wall exercises, light resistance exercises using towels, Theraband and water bottles, hand-eye coordination exercises, and fine motor activities. Exercises are performed five days per week, twice daily for 30 minutes per session, with 10 repetitions of each exercise.

    Behavioral: Home Exercise Program

Interventions

  • BehavioralSupervised Upper Extremity Physiotherapy Program

    Participants in the intervention group receive a 10-week rehabilitation program consisting of supervised upper extremity physiotherapy twice weekly for 45 minutes per session and a structured home exercise program on three non-treatment days per week. The home exercise program is identical in content to that of the control group and includes upper extremity range-of-motion exercises, stretching, wall exercises, light resistance exercises using towels, Theraband and water bottles, hand-eye coordination training, and fine motor activities. Home exercises are performed twice daily for 30 minutes per session, with 10 repetitions of each exercise. Supervised physiotherapy includes stretching, passive, active-assisted and active range-of-motion exercises, wand exercises, arm ergometer training, progressive strengthening using Theraband and 0.5 kg dumbbells, coordination exercises, and fine motor activities.

  • BehavioralHome Exercise Program

    Participants in the control group perform a structured home exercise program five days per week for 10 weeks. The program includes upper extremity range-of-motion exercises, stretching, wall exercises, light resistance exercises using towels, Theraband and water bottles, hand-eye coordination exercises, and fine motor activities. The exercises are performed twice daily for 30 minutes per session, with 10 repetitions of each exercise. The content of the home exercise program is the same as that prescribed to the intervention group. No supervised physiotherapy sessions are provided to the control group.

06

What researchers measure

Primary outcomes

  1. Change in Barthel Index Score

    The Barthel Index is used to assess independence in activities of daily living. Total scores range from 0 to 100, with higher scores indicating greater functional independence. Changes in Barthel Index scores from baseline to the end of the 10-week intervention are compared between the intervention and control groups.

    Time frame: Baseline (Week 1) and post-intervention (Week 10)

  2. Change in SF-36 Quality of Life Scores

    The SF-36 is used to assess health-related quality of life across eight domains. Scores for each domain range from 0 to 100, with higher scores indicating better health-related quality of life. Changes in scores from baseline to the end of the 10-week intervention are compared between the two groups.

    Time frame: Baseline (Week 1) and post-intervention (Week 10)

Secondary outcomes

  1. Change in Upper Extremity Range of Motion (ROM)

    Upper extremity range of motion is assessed using a goniometer. Measurements include shoulder flexion, extension and abduction; elbow flexion and extension; and wrist flexion and extension. Range of motion is recorded in degrees (°), with higher values indicating greater joint mobility. Changes from baseline to Week 10 are compared between the two groups.

    Time frame: Baseline (Week 1) and post-intervention (Week 10)

  2. Change in Pain Intensity Measured by Visual Analog Scale (VAS)

    Pain intensity is assessed using the Visual Analog Scale (VAS), a 10-cm scale ranging from 0 (no pain) to 10 (worst imaginable pain). Higher scores indicate greater pain intensity. Changes in VAS scores from baseline to the end of the 10-week intervention are compared between the intervention and control groups.

    Time frame: Baseline (Week 1) and post-intervention (Week 10)

  3. Change in Upper Extremity Sensory Function

    Upper extremity sensory function is assessed using superficial, deep, and cortical sensory tests, including temperature discrimination, sharp-dull discrimination, joint position sense (proprioception), and stereognosis. Changes in sensory function from baseline to Week 10 are evaluated in both groups.

    Time frame: Baseline (Week 1) and post-intervention (Week 10)

07

Study locations

2 sites
  • Avrasya Hospital Gaziosmanpaşa and zeytinburnu
    Istanbul, Turkey (Türkiye)
    • ali emre takkin, MsC · Contactaliemre.takkin@gmail.com · +90 507 154 48 87
    • Gülşen Yıldız, BSc · Principal investigator
  • Avrasya Hospital- Gaziosmanpaşa and Zeytinburnu
    Istanbul, Turkey (Türkiye)
    • Ali Emre Takkin, MsC · Contactaliemre.takkin@gmail.com · +90 507 154 48 87
    • Gülşen Yıldız, Bsc · Principal investigator
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Jan 2027, 2 months later.

Of 3,108 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 2 months is below that.

Counting every sponsor, half of 3,252 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 4, 2026
StartEst.
Nov 2, 2026
Primary completionEst.
Jan 11, 2027
CompletionEst.
Jan 20, 2027
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07915141
Lead sponsor
Istanbul Gelisim University
Responsible party
Sponsor
First posted
Nov 4, 2026
Start date
Nov 2, 2026 (estimated)
Primary completion
Jan 11, 2027 (estimated)
Completion
Jan 20, 2027 (estimated)
Last update
Nov 4, 2026

Study contacts

Gülşen Yıldız, Bachelor of Science - Lisans
Contact
gulsen.997178@gmail.com
+90 551 220 29 09
Hande B Besna Göçen, PhD
study chair · Istanbul Gelisim University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion